A standard of oral hormone replacement therapy in women after menopause – 1 mg of 17β-estradiol plus dydrogesterone?

Tomasz Pertyński; Grzegorz Stachowiak

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2005
vol. 4

Send email

Copy url:

abstract:

A standard of oral hormone replacement therapy in women after menopause – 1 mg of 17β-estradiol plus dydrogesterone?

Tomasz Pertyński

,

Grzegorz Stachowiak

Prz Menopauz 2005; 4: 60–64

Online publish date: 2005/08/31

View full text Get citation

Low-doses of natural estrogen – such as 17β-estradiol – plus progestin with low, or zero, androgenic, gluco- or mineralocorticoid properties (dydrogesterone) applied in women after menopause allow to reduce some of the typical HRT side effects – breast and endometrial cancers, abnormal uterine bleedings, or cardiovascular illnesses (atherosclerosis, arterial hypertension, venous thrombosis). Being an effective therapy of menopausal complaints and diseases, e.g. osteoporosis, it could be in the near future a standard of oral HRT.

keywords:

A standard of oral hormone replacement therapy in women after menopause – 1 mg of 17β-estradiol plus dydrogesterone?

Tomasz Pertyński , Grzegorz Stachowiak

dydrogesterone, 17β-estradiol, low-dose HRT, breast cancer, menopause

Tomasz Pertyński

,

Grzegorz Stachowiak